SB01 / Sinphar Pharma, National Health Research Institutes - LARVOL DELTA

SCHEMBL4796824: a multifaceted antitumor agent targeting microtubule dynamics, DNA damage, and Wnt/β-catenin signaling in ovarian cancer cells. (PubMed, J Ovarian Res) - "SCHEMBL4796824, a BPR0L075 derivative with antitumor properties, targets tubulin's colchicine binding site and induces DNA damage response in ovarian cancer...Notably, these effects were more pronounced in c-MYC amplified SK-OV-3 cells. In summary, SCHEMBL4796824 disrupts the canonical Wnt/β-catenin signaling, inducing DNA damage, and inhibits the Wnt/β-catenin/c-MYC axis, triggering cellular senescence in a pathway-dependent manner, hinting at a novel therapeutic approach."

Journal • Oncology • Ovarian Cancer • Solid Tumor • CHEK2 • MYC

BPR0L075 (SCB01A), a microtubule inhibitor targeting the colchicine binding site, induces immunogenic cell death (AACR 2024) - "We previously reported that BPR0L075 overcomes paclitaxel (microtubule stabilizer) resistance and induces vascular-disruption in vitro and in vivo...Using a known ICD inducer mitoxantrone as a positive control, both flow cytometric analysis and immunofluorescence staining assays demonstrated that BPR0L075 treatment led to a time- and dose-dependent translocation of calreticulin, an endoplasmic reticulum chaperone protein, on the plasma membrane of dying cells which sends an "eat me" signal...The appearance of the ICD biomarkers (calreticulin exposure, HMGB1 and ATP release) supports BPR0L075 as an ICD-inducing antimitotic agent. Further in vivo studies are warranted to delineate the effect of BPR0L075 on immune activation and recruitment of immune cells to the tumor microenvironment."

Immunogenic cell death • Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • CALR • HMGB1

To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - P2 | N=10 | Terminated | Sponsor: SynCore Biotechnology Co., Ltd. | N=37 ➔ 10

Enrollment change • Metastases • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - P2 | N=37 | Terminated | Sponsor: SynCore Biotechnology Co., Ltd. | N=10 ➔ 37

Enrollment change • Metastases • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Quorum sensing activity of Citrobacter amalonaticus L8A, a bacterium isolated from dental plaque. (PubMed) - Sci Rep - "Citrobacter amalonaticus strain L8A was identified and confirmed producing numerous types of AHL namely N-butyryl-L-homoserine lactone (C4-HSL), N-hexanoyl-L-homoserine lactone (C6-HSL), N-octanoyl-L-homoserine lactone (C8-HSL) and N-hexadecanoyl-L-homoserine lactone (C16-HSL). We performed the whole genome sequence analysis of this oral isolate where its genome sequence reveals the presence of QS signal synthase gene and our work will pave the ways to study the function of the related QS genes in this bacterium."

Journal • Biosimilar